aap Implantate AG / aap: Q3/2015 sales with EUR 8.4 million (+7%) in line with expectations; strong quarter in Biomaterials business (+27%) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) generated sales of EUR 8.4 million in the third quarter of 2015 (Q3/2014: EUR 7.8 million) according to preliminary figures, thereby achieving a result within the August forecast of EUR 7.5 million to EUR 9.0 million. Sales in the first nine months of the current financial year totalled EUR 22.0 million (9M/2014: EUR 22.1 million).


In EUR million		 Q3/2015 Q3/2014 Change
Sales 8.4 7.8 7%
Trauma 2.9 3.3 -14%
thereof LOQTEQ® 1.5 2.4 -37%
Biomaterials 5.4 4.2 27%
Projects 0.0 0.1 -92%
Other 0.1 0.2 -30%
 

 In EUR million		 9M/2015 9M/2014 Change
Sales 22.0 22.1 0%
Trauma 8.5 8.4 1%
thereof LOQTEQ® 5.2 5.3 -2%
Biomaterials 13.0 12.7 2%
Projects 0.2 0.3 -25%
Other 0.3 0.7 -59%
 
In the trauma business aap Implantate AG reached sales of EUR 2.9 million (Q3/2014: EUR 3.3 million) in the third quarter of 2015. The background to this decline were various developments in our strategically important growth markets in the BRICS and SMIT countries which weighed perceptibly on demand. Crucial were in particular a significantly reduced willingness to invest in China as a consequence of the recent stock market crash and the devaluation of the Chinese currency, the continuing weak Rouble including the trade sanctions imposed against Russia as well as the increasing unfavourable development of the Euro/Turkish Lira exchange rate in connection with a reimbursement reduction already implemented at the beginning of the year. Furthermore the first shipments to Brazil which were planned for the third quarter could not be carried out due to delays in product approval.
 
Although customer interest in aap Implantate AG's trauma portfolio remains intact, the company was unable to escape these external developments entirely. Furthermore, the US market has yet to make a significant contribution toward sales due to in part protracted administrative processes.
 
In contrast sales in the biomaterials business rose by 27% year-on-year in the third quarter of the current financial year to EUR 5.4 million (Q3/2014: EUR 4.2 million). The growth driver in the third quarter of 2015 was in particular the bone cement business with global leading companies.
 
In the first nine months of 2015, aap Implantate AG's sales in the trauma business totalled EUR 8.5 million (9M/2014: EUR 8.4 million). In the biomaterials business sales totalled EUR 13.0 million (9M/2014: EUR 12.7 million) in the nine-month period 2015.
 
The preliminary results contained in this press release are based on management's initial analysis of operations for the period ended on 30 September 2015, and are therefore subject to change. aap Implantate AG plans to announce its final results for the third quarter respectively the first nine months of 2015 on 13 November 2015. 

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ® a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire
HUG#1958424

--- End of Message ---

aap Implantate AG
Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Share
© GlobeNewswire - 2015